Stem Cell Transplantation for Hurler

This study is ongoing, but not recruiting participants.

Study NCT00176917 Information provided by Masonic Cancer Center, University of Minnesota

First Received: September 12, 2005 Last Updated: July 28, 2009 History of Changes

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Conditions:	Mucopolysaccharidosis I Mucopolysaccharidosis VI Mannosidosis Mucolipidosis Type II (I-cell Disease)
Interventions:	Procedure: Stem Cell Transplant Drug: Busulfan, Cyclophosphamide, ATG

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Transplant Patients	Patients that received hematopoietic stem cell transplant.

Participant Flow: Overall Study

	Transplant Patients
STARTED	41
COMPLETED	41
NOT COMPLETED	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Transplant Patients	Patients that received hematopoietic stem cell transplant.

Baseline Measures

	Transplant Patients
Number of Participants [units: participants]	41
Age [units: participants]
<=18 years	41
Between 18 and 65 years	0
>=65 years	0
Age [units: years] Mean ± Standard Deviation	1.8 ± 1.4
Gender [units: participants]
Female	23
Male	18
Region of Enrollment [units: participants]
United States	41

Outcome Measures

Show All Outcome Measures

1. Primary:

Mean Percentage of Donor Cells in Study Population (Chimerism).

Hide Outcome Measure 1

Measure Type	Primary
Measure Title	Mean Percentage of Donor Cells in Study Population (Chimerism).
Measure Description	Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).
Time Frame	at 21 days, 42 days, 60 days, 100 days, 6 months, and 1 year
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Day 21 (24 patients included), Day 42 (15 pts), Day 60 (29 pts), Day 100 (25 pts), 6 Months (18 pts), 1 Year (16 pts).

Reporting Groups

	Description
Transplant Patients	Patients that received hematopoietic stem cell transplant.

Measured Values

	Transplant Patients
Number of Participants Analyzed [units: participants]	41
Mean Percentage of Donor Cells in Study Population (Chimerism). [units: Percentage] Mean ± Standard Deviation
21 Days Post Transplant	85.8 ± 28.4
42 Days Post Transplant	73.2 ± 31.6
60 Days Post Transplant	84.6 ± 27.9
100 Days Post Transplant	81.1 ± 26.8
6 Months Post Transplant	81.6 ± 29.6
1 Year Post Transplant	91.5 ± 18.8

No statistical analysis provided for Mean Percentage of Donor Cells in Study Population (Chimerism).

2. Secondary:

Number of Patients Surviving on Study

Show Outcome Measure 2

3. Secondary:

Number of Patients Who Failed Engraftment.

Show Outcome Measure 3

4. Secondary:

Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report. For adverse events, see Secondary Outcome Measures #3 and #4.

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report.

For adverse events, see Secondary Outcome Measures #3 and #4.

Results Point of Contact:

Name/Title: Paul J. Orchard, M.D.
Organization: Masonic Cancer Center, University of Minnesota
phone: 612-626-2313
e-mail: orcha001@umn.edu

No publications provided

Responsible Party:	Masonic Cancer Center at the University of Minnesota ( Orchard, Paul J., MD )
Study ID Numbers:	0104M93821, MT1999-07
Study First Received:	September 12, 2005
Results First Received:	July 28, 2009
Last Updated:	July 28, 2009
ClinicalTrials.gov Identifier:	NCT00176917 History of Changes
Health Authority:	United States: Institutional Review Board